Completed PHASE3 INTERVENTIONAL NCT00034762
Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conditions
Alzheimer Disease Dementia Mental Disorders
Interventions
risperidone
Updated 1 time since 2024 Last updated: Jan 31, 2011 Started: Dec 31, 2000 Completion: Jan 31, 2003
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE3 clinical study on Alzheimer Disease and Dementia, this trial is completed. The trial is conducted by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and has accumulated 1 data snapshot since 2000. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
1 version recorded Completed — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Data source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.